Engineered E. coli Shows Promise in Tumor Treatment

A study published on March 17th in PLOS Biology suggests that engineered Escherichia coli Nissle 1917 (EcN) may be effective in treating cancerous tumors in mice. The research was conducted by Tianyu Jiang and colleagues at Shandong University, Qingdao, China.

A Novel Therapeutic Approach

Researchers utilized Escherichia coli Nissle 1917 (EcN) as a foundational element to synthesize Romidepsin (FK228), an FDA-approved drug recognized for its anti-tumor properties. Through advanced genetic and genomic engineering, a novel bacterial strain capable of producing Romidepsin was successfully created.

This newly engineered strain was then introduced into a mouse model, specifically developed with tumor-producing breast cancer cells, to evaluate its therapeutic potential.

Key Findings: Targeted Dual-Action Therapy

The findings from the study indicated that the engineered EcN effectively colonized tumors. Crucially, it released Romidepsin FK228 both in vitro (in laboratory experiments) and in vivo (within living organisms) under various conditions. This mechanism positioned it as a highly targeted tumor therapy.

The authors note that EcN's tumor colonization, combined with Romidepsin's anticancer activity, forms a dual-action cancer therapy.

Future Research and Development

While the initial results are promising, future research is imperative. Further studies are required to test this treatment in human subjects to confirm its safety and efficacy.

Additionally, subsequent investigations must focus on identifying any potential adverse outcomes associated with the therapy. Developing reliable methods for eliminating the bacteria after the completion of treatment is also a critical area for ongoing research and development.